Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
mbines the rigor of a big pharmaceutical company with theingenuity and energy of a small company creating an environment forefficient and effective pre-clinical and clinical program decisions. Itsscientific founders have successfully worked together for more than adecade and were pivotal in the discovery of a number of inflammatory drugsincluding Singulair(R). The drug hunters at Amira are
Date:6/2/2008